New Results
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against autoimmune diseases
Ronghan Liu, Yuehong Chen, Shuya Wang, Yazhou Cui, Xiangli Zhang, Zi-Ning Lei, Aubryanna Hettinghouse, Jody Liu, Wenyu Fu, Zhe-Sheng Chen, Chuanju Liu
doi: https://doi.org/10.1101/584540
Ronghan Liu
1NYU School of Medicine
Yuehong Chen
1NYU School of Medicine
Shuya Wang
1NYU School of Medicine
Yazhou Cui
1NYU School of Medicine
Xiangli Zhang
1NYU School of Medicine
Zi-Ning Lei
2St. John’s University
Aubryanna Hettinghouse
1NYU School of Medicine
Jody Liu
1NYU School of Medicine
Wenyu Fu
1NYU School of Medicine
Zhe-Sheng Chen
2St. John’s University
Chuanju Liu
1NYU School of Medicine
Posted March 21, 2019.
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against autoimmune diseases
Ronghan Liu, Yuehong Chen, Shuya Wang, Yazhou Cui, Xiangli Zhang, Zi-Ning Lei, Aubryanna Hettinghouse, Jody Liu, Wenyu Fu, Zhe-Sheng Chen, Chuanju Liu
bioRxiv 584540; doi: https://doi.org/10.1101/584540
Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against autoimmune diseases
Ronghan Liu, Yuehong Chen, Shuya Wang, Yazhou Cui, Xiangli Zhang, Zi-Ning Lei, Aubryanna Hettinghouse, Jody Liu, Wenyu Fu, Zhe-Sheng Chen, Chuanju Liu
bioRxiv 584540; doi: https://doi.org/10.1101/584540
Subject Area
Subject Areas
- Biochemistry (11718)
- Bioengineering (8724)
- Bioinformatics (29132)
- Biophysics (14936)
- Cancer Biology (12051)
- Cell Biology (17360)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14146)
- Epidemiology (2067)
- Evolutionary Biology (18269)
- Genetics (12223)
- Genomics (16768)
- Immunology (11844)
- Microbiology (28016)
- Molecular Biology (11560)
- Neuroscience (60822)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10401)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)